Please visit answersincme.com/REE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Adam Friedman, MD. In this activity, an expert in the management of chronic spontaneous urticaria (CSU) discusses how targeted therapies fit within evolving treatment algorithms and how to integrate them appropriately into clinical practice for improved patient outcomes. Upon completion of this activity, participants should be better able to: Evaluate the rationale for targeted therapies in patients with CSU; Outline the different pathogenic mechanisms in CSU, with a focus on their relationship to type 2 inflammation, and the clinical implications of these different pathways; and Design treatment plans that optimize the use of targeted therapies in CSU, based on the latest evidence and expert insights.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related